Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.0K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.0K
Amyloid Fibrils03:03

Amyloid Fibrils

11.9K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Segmental and Multifocal Isolated Dystonias: Similarities and Differences.

Movement disorders clinical practice·2025
Same author

Applying Wearable Sensors and Machine Learning to the Diagnostic Challenge of Distinguishing Parkinson's Disease from Other Forms of Parkinsonism.

Biomedicines·2025
Same author

Tremor in cervical dystonia.

Dystonia (Lausanne, Switzerland)·2024
Same author

Genetic Risk Factors in Isolated Dystonia Escape Genome-Wide Association Studies.

Movement disorders : official journal of the Movement Disorder Society·2024
Same author

Longitudinal predictors of health-related quality of life in isolated dystonia.

Journal of neurology·2023
Same author

Spirituality in Parkinson's Disease within a Sample from the USA.

Journal of religion and health·2023
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Jan 30, 2026

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.4K

Parkinson's Disease.

Stephen G Reich1, Joseph M Savitt1

  • 1Department of Neurology, University of Maryland School of Medicine, 110 South Paca Street, 3rd Floor, Baltimore, MD 21201, USA.

The Medical Clinics of North America
|February 2, 2019
PubMed
Summary
This summary is machine-generated.

Parkinson disease (PD) diagnosis requires motor symptoms like bradykinesia and tremor or rigidity, with no alternative causes. Nonmotor and prodromal symptoms are also key, and levodopa remains the primary treatment.

Keywords:
DyskinesiasLevodopaParkinsonismParkinson’s diseaseREM sleep behavioral disorderTremor

More Related Videos

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
10:32

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

56.3K
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.9K

Related Experiment Videos

Last Updated: Jan 30, 2026

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.4K
Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
10:32

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

56.3K
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.9K

Area of Science:

  • Neurology
  • Movement Disorders

Background:

  • Parkinson disease (PD) diagnosis relies on cardinal motor signs: bradykinesia, resting tremor, or rigidity.
  • Absence of alternative parkinsonism causes is crucial for PD diagnosis.
  • Nonmotor symptoms, including neuropsychiatric, autonomic, sleep, and sensory issues, are prevalent and can precede motor deficits (prodromal PD).

Purpose of the Study:

  • To outline the diagnostic criteria for Parkinson disease.
  • To highlight the significance of nonmotor and prodromal symptoms in PD.
  • To review current and advanced therapeutic options for Parkinson disease.

Main Methods:

  • Clinical examination for motor signs (bradykinesia, tremor, rigidity).
  • Patient history to exclude alternative causes of parkinsonism.
  • Classification of nonmotor symptoms into neuropsychiatric, autonomic, sleep, and sensory domains.

Main Results:

  • Diagnostic criteria for Parkinson disease established.
  • Identification of prodromal nonmotor symptoms preceding motor onset.
  • Levodopa confirmed as the primary pharmacological treatment.

Conclusions:

  • Accurate diagnosis of Parkinson disease integrates motor and nonmotor features.
  • Understanding prodromal symptoms aids in early identification and management.
  • Comprehensive treatment strategies include pharmacotherapy (levodopa) and advanced interventions like deep brain stimulation.